INTRODUCTION
============

Myotubular myopathy (MTM), an X-linked congenital myopathy, is among the most severe childhood neuromuscular disorders ([@b18-0050852]). Affected boys usually present in infancy with hypotonia, weakness and respiratory failure, and nearly half die in the first year of life ([@b16-0050852]; [@b26-0050852]). Those who survive have substantial disability, most often never achieving independent ambulation and usually requiring continuous ventilator support, and suffer premature lethality. There are no known treatments or disease-modifying therapies for this devastating disorder ([@b12-0050852]).

MTM is the most common subtype of a larger group of childhood muscle diseases called centronuclear myopathies (CNMs) ([@b18-0050852]). CNMs as a group are united by common features on muscle biopsy, including prominent centrally located nuclei, type I fiber predominance and hypotrophy, and irregular staining with oxidative enzymes ([@b31-0050852]). Recent studies also suggest that there are common pathomechanisms shared between subtypes of CNMs. Currently, mutations in four genes are associated with CNM: dynamin-2 (*DNM2*) ([@b6-0050852]), bridging integrator 1 (*BIN1*) ([@b30-0050852]), the skeletal muscle ryanodine receptor (*RYR1*) ([@b40-0050852]) and myotubularin (*MTM1*) ([@b22-0050852]).

The only identified cause of MTM is mutation in *MTM1* ([@b12-0050852]; [@b22-0050852]; [@b16-0050852]). Myotubularin is a phosphoinositide phosphatase that regulates vesicle sorting within and through endosomal compartments ([@b37-0050852]; [@b11-0050852]; [@b13-0050852]). Advances in our knowledge of myotubularin function and MTM disease pathogenesis have been greatly accelerated by the establishment of vertebrate models of the disease. In particular, recent work from several groups has identified a role for myotubularin in skeletal muscle in the formation and maintenance of the triad, the structure responsible for mediating excitation-contraction coupling ([@b4-0050852]; [@b14-0050852]; [@b3-0050852]). Additional studies on CNMs caused by *BIN1*, *RYR1* and *DNM2* mutations have also documented structural and/or functional abnormalities in the triad ([@b3-0050852]; [@b39-0050852]). On the basis of these data, an emerging theory concerning MTM specifically, and CNMs in general, is that a primary mechanism of disease is abnormal Ca^2+^ homeostasis and impaired excitation-contraction coupling.

Myotubularin probably also performs additional functions within skeletal muscle that contribute to the disease phenotype. For example, a direct interaction between myotubularin and desmin was recently established, and examination of this interaction revealed that myotubularin might regulate the intracellular architecture and mitochondrial homeostasis within the myofiber ([@b17-0050852]). Using a zebrafish model of MTM, we recently demonstrated that *mtm1* knockdown disturbs neuromuscular junction (NMJ) organization and that exposure to an acetylcholinesterase inhibitor improves motor function in morphant embryos ([@b36-0050852]). There is also evidence from previous ultrastructural examination of skeletal muscle from single cases of CNM or MTM for abnormalities in NMJ structure ([@b5-0050852]; [@b15-0050852]; [@b24-0050852]). On the basis of these results, as well as the established link between endosomes and the regulation of NMJs ([@b7-0050852]), we hypothesized that NMJ abnormalities (1) could be an additional contributing factor in MTM disease pathogenesis and (2) could be subject to modification via drug treatment.

To test these hypotheses, we used two existing murine models of MTM. The first, a gene knockout (KO) of myotubularin (*Mtm1*), has a severe phenotype, with onset of motor pathology at 2--4 weeks of age and death between 2--3 months of age ([@b9-0050852]). The second, a gene knock-in (KI) of a missense mutation (p.R69C) associated with mild clinical symptoms in individuals with MTM ([@b32-0050852]), displays motor dysfunction starting at 3 months of age and death at approximately 12 months ([@b33-0050852]). Both models exhibit the classic histopathological features observed in the skeletal muscles of individuals with MTM. In this study, using behavioral, neurodiagnostic and histopathological evaluations, we demonstrate that MTM mouse models have the characteristic features of dysfunction at the NMJ. Furthermore, using a randomized placebo-controlled study, we determine that treatment with the acetylcholinesterase inhibitor pyridostigmine improves MTM KI mouse motor function. In all, we describe a new aspect of pathogenesis in MTM and identify a promising therapy for this currently untreatable disease.

RESULTS
=======

MTM mice have phenotypic and neurodiagnostic features of a disorder of NMJ transmission
---------------------------------------------------------------------------------------

We evaluated these models for evidence of a clinical disorder of NMJ transmission. In humans, disorders of the NMJ are characterized by exercise intolerance and fatigable weakness ([@b19-0050852]). We examined these parameters in KI mice and their wild-type (WT) littermates. Exercise tolerance was measured by testing the ability of the mice to remain on a treadmill set at low speed (8 m/minute). As expected, all WT mice were able to walk for at least 25 minutes without difficulties. By contrast, KI mice could only tolerate an average of 8 minutes before stopping ([Fig. 1A](#f1-0050852){ref-type="fig"}). Fatigable weakness was determined by measuring force generation during a series of repetitive forelimb grip measurements using a dynamometer ([Fig. 1B](#f1-0050852){ref-type="fig"}). WT mice displayed no change in strength between grip 1 and grip 20, whereas KI mice exhibited a 40.1% decline in force generation. KI mice thus demonstrate both exercise intolerance and fatigable weakness. Of note, KO mice were too weak to tolerate these tests.

Two neurodiagnostic studies of NMJ dysfunction have been established in mouse models of a human NMJ disorder called myasthenia gravis ([@b43-0050852]). The first is a pharmacological test whereby strength is measured before and after administration of a short-acting acetylcholinesterase inhibitor. We performed this test by measuring grip strength before and after neostigmine infusion. WT mice had no change in force generation with drug treatment. By contrast, KI mice experienced a 116% increase in grip strength after neostigmine administration (*n*=12, *P*\<0.001). The second study is a repetitive stimulation nerve conduction study, which is a diagnostic gold standard in individuals with NMJ disorders. A positive result is indicated by a decremental response of 10% or greater in the amplitude of compound muscle action potentials with 3-Hz repetitive stimulation. All control mice tested had a normal response (i.e. no decrement \>10%). Conversely, 2/5 of KI mice and 12/18 KO mice had a positive test (≥10% decrement), with an average decrement in KO mice of 11.5±1.5%, compared with an average value of 2.0±0.9% for WT (*P*=0.0002). Sample studies from a control and a KO mouse are shown in [Fig. 1C](#f1-0050852){ref-type="fig"}. In combination with the 'clinical' assessment, both diagnostic tests strongly support the presence of an NMJ defect in MTM mouse models.

![**MTM mice have a disorder of NMJ transmission.** (A) 5-month-old KI mice and WT littermates were placed on a treadmill at 8 m/minute. All WT mice remained on for 25 minutes, whereas KI mice remained on for only 8.4±0.5 minutes (*n*=5, *P*\<0.0001). (B) Grip fatigue was assayed by measuring forelimb force generation over 20 consecutive grips. Data are expressed as the % strength difference between grips 20 and 1. For WT animals, grip 20 was 100.4±4.6% the value of grip 1. For KI animals, grip 20 was 59.9±4.3% the value of grip 1 (*n*=5 animals, *P*\<0.0001). Of note, KO mice were too weak to tolerate either the treadmill or the grip fatigue tests. (C) Compound motor action potentials (CMAPs) recorded from gastrocnemius with 3-Hz repetitive nerve stimulation at the sciatic notch. Depicted are CMAPs from a train of ten stimuli. % decrement (dec) was determined by comparing the CMAP amplitudes of the first and fifth peaks. In these traces, WT CMAP exhibited a 4% decrement, whereas KO CMAP showed a 16% decrement.](DMM009746F1){#f1-0050852}

MTM mouse models exhibit histopathological abnormalities at the NMJ
-------------------------------------------------------------------

To better understand the basis of the NMJ phenotype that is present in MTM mice, we performed a histopathological analysis of junctions in WT and *Mtm1* KO animals. We first imaged NMJs in situ in skeletal muscle using fluorescently conjugated α-bungarotoxin to label acetylcholine receptors (AChRs) ([Fig. 2](#f2-0050852){ref-type="fig"}). In WT mice, staining of whole diaphragm demonstrated a tight band of receptors in the center of the tissue. Conversely, staining of diaphragm in KO mice revealed a dispersed and disorganized band of AChRs ([Fig. 2A](#f2-0050852){ref-type="fig"}). We quantified this difference by measuring the maximum width of α-bungarotoxin staining in each sample. KO mice had a significantly greater width of staining as compared with controls (0.37±0.01 vs 0.86±0.03, *n*=5, *P*\<0.0001).

![**NMJ abnormalities in MTM KO mice.** (A) α-bungarotoxin--Alexa-Fluor-594 staining of isolated whole-mount diaphragm muscle from 5-week-old WT and MTM KO mice. WT diaphragms show a discrete, concentrated band of staining, whereas KO mice had a more diffuse and less organized pattern of staining. Scale bars: 110 μm. (B) Confocal image of α-bungarotoxin staining from an isolated tibialis anterior myofiber from 5-week-old WT and KO mice. Individual junctions from KOs have a similar overall appearance to those from WT but are significantly larger. Scale bar: 20 μm. Right panel: quantification of the overall area of NMJs as determined from images similar to that on the left. Values (in arbitrary units) were 104.0±9.9 (WT) vs 136.7±10.1 (KO) (*n*=30 junctions, *P*=0.04).](DMM009746F2){#f2-0050852}

We next analyzed individual junctions by staining isolated myofibers with α-bungarotoxin. Junctions from KO animals retained a normal overall appearance of staining, but were substantially larger than junctions from WT animals ([Fig. 2B](#f2-0050852){ref-type="fig"}). We performed a similar analysis in KI mice, and found that NMJs were 30% larger than in age-matched littermates (*n*=30, *P*=0.01).

We lastly examined NMJ ultrastructure using electron microscopy ([Fig. 3](#f3-0050852){ref-type="fig"}). Muscle from WT mice exhibited dense, membranous areas with deep and complex invaginations that are typical of murine NMJs. Muscle from KO animals, conversely, contained NMJs with multiple abnormalities, including severe simplification of the post-synaptic junctional appearance with shallower and less complex invaginations. In addition, the subjunctional sarcoplasm appeared disorganized and contained many vacuolar structures. Of note, the density along the immediate postsynaptic membrane appeared qualitatively similar to that of WT junctions, in keeping with the light microscopic findings with α-bungarotoxin. In all, MTM mice have structurally abnormal NMJs, exhibiting both increased size as well as reduced complexity.

Altered neuregulin signaling as a mechanism underlying NMJ size changes in MTM mice
-----------------------------------------------------------------------------------

We then investigated potential pathomechanisms for the observed structural changes in NMJs from MTM mice. To determine whether the increase in junction size correlated with changes in gene expression, expression levels of components of the NMJ were examined by quantitative reverse-transcriptase PCR (qRT-PCR). Consistent with our histochemical data, expression of several NMJ-associated transcripts (*AchE*, *Chrna*, *Chrng*, *Chrnd*, *Chrne* and *MuSK*) was increased in both KO and KI muscle ([Fig. 4A](#f4-0050852){ref-type="fig"}). These changes were detected at early phenotypic stages and were maintained in older animals as well. Neuregulin (*Nrg1*) gene expression was also increased; this observation, in combination with increased AChR subunit expression, is suggestive of upregulation of the neuregulin (NRG) signaling pathway ([@b35-0050852]). Consequently, the NRG pathway was evaluated by measuring ERK phosphorylation, a known downstream modification of NRG signaling ([@b42-0050852]). Consistent with increased NRG signaling, phosphorylated ERK (pERK) levels were significantly increased in KO mice as compared with WT littermates ([Fig. 4B](#f4-0050852){ref-type="fig"}).

![**Ultrastructural abnormalities in the NMJs of MTM KO mice.** Ultrastructural examination of NMJs from the tibialis anterior muscle from 4-week-old WT and KO mice. Low-magnification images (top panels) illustrate the presence of vacuoles (arrows) and disorganized, amorphous material in the subjunctional space (\*\*\*) in KO mice. Scale bar: 2 μm. High-magnification images (bottom panels) reveal simplification of the post junctional folds (arrows) in KO mice. Scale bar: 1 μm.](DMM009746F3){#f3-0050852}

![**Alterations in gene expression and AChR localization in MTM KO mice.** (A) Gene expression analysis of components of the NMJ using qRT-PCR. RNA was pooled from quadriceps muscle from 21- and 35-day-old KOs and 30-and 160-day-old KIs. All values are normalized with GAPDH and then expressed as a fold comparison with age-matched WT littermate values. Significant increases were observed in both young and old KO and KI animals for several components of the NMJ as well as for neuregulin (NRG1). The relative mRNA levels of *AchE*, *Chrna1*, *Chrng*, *Chrnd*, *Chrne*, *MuSK* and *Nrg1* from quadriceps of 21 (*n*=9)- or 35 (*n*=8)-day-old *Mtm1* KO mice and 30 (*n*=5)- or 160 (*n*=5)-day-old *Mtm1* KI mice were quantified by qRT-PCR, normalized to GAPDH expression, and compared with WT levels. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001 (vs WT). (B) Western blot analysis of protein extracts from 5-week-old WT and KO quadriceps muscle using antibodies to ERK and pERK. Right panel shows quantification of bands by densitometry. Values (pERK:ERK) were 0.53±0.05 (WT) and 1.14±0.15 (KO) (*n*=3, *P*=0.01). Mr, molecular weight. (C) Western blot analysis of protein extracts from myotubes differentiated from pools of myoblasts isolated from 4-week-old WT and KO animals. Blots were probed with antibodies to AChR, actin and Rab5 \[an endosomal marker used to verify successful fractionation of endosomes (Endo) from plasma membrane (PM) (data not shown)\]. Quantification of bands from the blot are shown in the right panel. Data represent the ratio of AChR:actin for each subcellular fraction. Actual values were as follows: 1.56 (WT PM), 0.81 (WT ENDO), 1.21 (KO PM) and 3.56 (KO ENDO). (D) α-bungarotoxin labeling of differentiated myotubes. Cells were incubated in Alexa-Fluor-488-conjugated α-bungarotoxin (Invitrogen) for 45 minutes and then either immediately imaged or else imaged 45 minutes or 4 hours after removal of the α-bungarotoxin. Images shown are from 4 hours after removal of α-bungarotoxin. In WT myotubes (left panel), labeling is found along the outer membrane surface, whereas, in KO myotubes (right panel), the staining is detected in puncta within the cytoplasm (arrows) (*n*=10 per condition).](DMM009746F4){#f4-0050852}

Abnormal membrane traffic as a mechanism underlying NMJ structural changes in MTM mice
--------------------------------------------------------------------------------------

Changes in gene expression and abnormal pERK levels probably do not account for the ultrastructural changes in the NMJs. Given the simplified, vacuolated appearance of the junctions, one possible explanation is aberrant regulation of junctional membrane turnover. To test for this, protein extracts from differentiated myotubes were fractionated to measure the levels of AChR at the plasma membrane and within the internalized endosomal fraction. A significant increase in the overall amount and ratio of AChRs associated with the endosomal fraction was detected in KO myotubes ([Fig. 4C](#f4-0050852){ref-type="fig"}). AChR recycling was further studied by examining receptor internalization in differentiated myotubes after a pulsed exposure to fluorescently conjugated α-bungarotoxin. After a 1-hour pulse, there was no difference in α-bungarotoxin staining. By contrast, after a 4-hour chase, there was a visible increase in the number of α-bungarotoxin puncta within *Mtm1* KO myotubes, consistent with a failure of export from the endosomal fraction ([Fig. 4D](#f4-0050852){ref-type="fig"}). In combination, these data suggest abnormal NMJ trafficking as one potential explanation for the observed ultrastructural abnormalities. These data are also consistent with our observation of mislocalized and disorganized NMJs as seen with examination of muscle in situ ([Fig. 2A](#f2-0050852){ref-type="fig"}).

Treatment with pyridostigmine improves the motor phenotype in MTM KI mice
-------------------------------------------------------------------------

Treatment with acetylcholinesterase inhibitors is beneficial in individuals with primary diseases of the NMJ ([@b1-0050852]; [@b38-0050852]). We thus hypothesized that such treatment should improve aspects of the motor phenotype in MTM mice as well. To test this, we performed a randomized trial involving pyridostigmine, an acetylcholinesterase inhibitor widely used in humans ([@b25-0050852]). Starting at 5 months of age, KI animals were given intraperitoneal (IP) injections of either phosphate-buffered saline (PBS) or pyridostigmine four times daily for a total of 4 weeks. Animals were tested for grip fatigue and treadmill endurance immediately prior to initiation of the trial, at 2 and 4 weeks of treatment, and 2 weeks after treatment was discontinued. No statistical difference was seen in either measure prior to treatment. PBS-treated animals experienced an increase in grip fatigue and a decline in treadmill endurance during the 4-week period of the drug trial. Conversely, pyridostigmine-treated animals showed a modest improvement in grip fatigue and a substantial change in treadmill endurance at all time points examined. Both measures were statistically significantly improved as compared with PBS-treated littermates ([Fig. 5](#f5-0050852){ref-type="fig"}). Of note, these improvements persisted beyond the conclusion of the trial.

![**Pyridostigmine treatment improves motor function in MTM KI animals.** KI animals were treated with either PBS or pyridostigmine (PYR) four times daily for 30 days (*n*=8 per condition). Measurements were made at the initiation of the trial, 16 and 30 days into the trial (D=16 and D=30), and 2 weeks after conclusion of the trial (2wk PT). Examiners were blinded to experimental condition. Measurements were recorded as per [Fig. 1](#f1-0050852){ref-type="fig"}. (A) There was significant reduction in grip fatigue with PYR treatment. This improvement reached statistical significance at day 16 and 2 weeks post treatment, and was suggestive but not significant at day 30. Data are expressed as the percentage of grip 20/grip 1. For PBS, results were: 84.5±4.8% (D=0), 64.2±3.9% (D=16), 78.0±7.3% (D=30) and 67.0±5.9% (2wk PT). For PYR, results were: 88.4±11.0% (D=0; n.s. vs PBS D=0), 85.2±4.5% (D=16; \**P*=0.001 vs PBS D=16), 87.7±6.6% (D=30; *P*=0.17 vs PBS D=30) and 86.8%±6.9% (2wk PT; \*\**P*=0.02 vs PBS 2wk PT). (B) Treatment with PYR significantly improved treadmill endurance at all times tested. For PBS treatment, times were (in minutes): 5.6±1.4 (D=0), 2.3±1.3 (D=16), 3.1±1.3 (D=30) and 4.4±1.4 (2wk PT). For PYR treatment, times were: 6.9±1.2 (D=0; n.s. vs PBS D=0), 9.0±0.9 (D=16; \**P*=0.0003 vs PBS D=16), 9.0±0.9 (D=30; \*\**P*=0.002 vs PBS D=30) and 8.8±1.0 (2wk PT; \*\*\**P*=0.02 vs PBS 2wk PT).](DMM009746F5){#f5-0050852}

DISCUSSION
==========

In summary, we demonstrate that (1) MTM mice have features of a clinical disorder of NMJ transmission, (2) these clinical changes are correlated with structural changes in the NMJ, and (3) pyridostigmine, an acetylcholinesterase inhibitor, improves aspects of the MTM mouse motor phenotype. These results are important because they identify a previously unknown aspect of MTM disease pathogenesis and provide preclinical evidence (in the form of a placebo-controlled study) for the first potential therapy for this devastating disease.

Additional support for the presence of NMJ pathology in MTM and for the potential efficacy of pyridostigmine comes from two recent case studies. The first study reported four individuals (one with MTM and three with genetically undefined CNMs) with the clinical and electrodiagnostic features of a disorder of NMJ transmission ([@b36-0050852]). All four individuals had at least some positive benefit when treated with pyridostigmine, with one individual regaining ambulation after starting medication. The second study documented a single case of CNM (genetic cause unknown) with features of an NMJ disorder and a positive response to pyridostigmine ([@b24-0050852]). This case additionally included ultrastructural analysis that revealed simplified postsynaptic regions that were similar in appearance to the MTM KO mice ([Fig. 4](#f4-0050852){ref-type="fig"}). Similar findings were reported in a case of MTM (without genetic confirmation) ([@b5-0050852]; [@b15-0050852]; [@b24-0050852]). These results support the consideration of pyridostigmine (or other modulators of NMJ function) for the treatment of individuals with MTM, and also suggest that NMJ pathology might be a shared feature of all CNMs.

An important issue raised by this study is the nature of the pathomechanisms responsible for NMJ pathology in the setting of myotubularin mutation. The NMJs in the mouse models are both larger and greatly simplified in ultrastructure compared with WT. Our data support a hypothesis whereby the increased junctional size is due to abnormal NRG signaling and the aberrant junctional structure is caused by defective AChR trafficking. Given that myotubularin is a known regulator of endosomal dynamics ([@b13-0050852]; [@b29-0050852]), and that both AChR trafficking and NRG signaling are dependent on endocytic machinery ([@b8-0050852]; [@b44-0050852]; [@b7-0050852]), this hypothesis plausibly fits with the loss of myotubularin function. At present, the abnormalities in receptor recycling do not completely explain the ultrastructural changes observed on electron microscopy. Other factors are likely to contribute, including changes induced by muscle inactivity and the potential role of dysregulated Ca^2+^ homeostasis. Also, given the fact that knockout of desmin in mice also causes NMJ abnormalities (including disorganization and simplification of the junctions) ([@b2-0050852]), it is possible that some of the NMJ abnormalities in the MTM KO mice result from the loss of the recently described desmin-myotubularin interactions ([@b17-0050852]). Future experimentation will be required to better test these concepts and to further delineate the mechanism(s) of pathology.

The need for therapy development for MTM is crucial. Approximately 50% of boys with MTM die in the first year of life, and those that survive have substantial disability in the form of chronic ventilator dependence and impaired ambulation ([@b12-0050852]; [@b16-0050852]; [@b26-0050852]). Although pyridostigmine is not expected to be a curative therapy, the possibility that it could improve motor function in patients and thus positively alter disease course makes it an extremely attractive therapeutic candidate. This is especially true given that pyridostigmine is routinely used in children and adults without significant adverse effects ([@b38-0050852]; [@b25-0050852]). In addition, pyridostigmine is unlikely to interfere with additional therapeutic strategies being considered for MTM \[such as, for example, myostatin inhibition ([@b23-0050852]) or gene therapy ([@b10-0050852])\], and thus would make a useful adjunct treatment strategy. In the future, it will be important to compare the effect of pyridostigmine with 3,4-DAP (diaminopyridine), a drug that promotes the release of acetylcholine from presynaptic nerve termini and has been effective in Lambert-Eaton syndrome ([@b41-0050852]) and in some cases of congenital myasthenic syndrome ([@b20-0050852]). It is possible that 3,4-DAP is equally or more effective than pyridostigmine, and that the two drugs in combination could synergistically improve motor function.

In conclusion, using murine models of MTM, we have identified a previously unknown disease pathomechanism and a potential therapy based on this observation. On the basis of the results presented in this study, along with case reports supporting an NMJ phenotype in individuals with CNM, we propose that pyridostigmine would make an excellent therapeutic candidate to be tested in the clinical trial setting.

METHODS
=======

Mice
----

*Mtm1* KO and KI mice have been described previously ([@b9-0050852]; [@b33-0050852]) and were maintained on a C56BL6 background (129PAS background for qRT-PCR) according to IUCUC guidelines at the various institutions (University of Michigan, Nationwide Children's Hospital and Genethon). All studies were conducted on hemizygous affected male animals carrying the indicated mutations and age-matched male WT littermates.

Grip fatigue testing
--------------------

Grip fatigue testing was performed as described previously ([@b28-0050852]). Force generated after treadmill walking from each of 20 consecutive grip strength measurements was determined using a dynamometer (Columbus Instruments). Grip fatigue was calculated as the percent difference in force between the twentieth and the first grip.

Neostigmine challenge
---------------------

Neostigmine challenge was performed as described previously ([@b43-0050852]). Grip strength was measured as above, and then a neostigmine bromide dose of 0.75 μg was administered with 0.3 μg atropine sulfate (both from Sigma) mixed in PBS and injected IP in 50 μl total volume. Five minutes later, grip strength was measured as above.

Repetitive nerve stimulation testing
------------------------------------

Repetitive nerve stimulation testing was performed as described previously ([@b43-0050852]). Animals were anesthetized with ketamine. A stimulating electrode was placed at the sciatic notch and a recording electrode was placed in the corresponding gastrocnemius muscle. First, a single super-maximal stimulation was given to verify the ability to detect a compound muscle action potential (CMAP). Then, a train of stimuli at 3 Hz was applied and the resulting CMAPs recorded using a Viking nerve conduction recording system.

Pyridostigmine trial
--------------------

Following a baseline \[Day (D)=0\] determination of grip strength fatigue and treadmill endurance, 0.1 μg/g of pyridostigmine was administered four times a day to 5-month-old KI mice for 30 days. Grip strength fatigue and treadmill endurance were determined 16 (D=16) and 30 (D=30) days after the initiation of treatment and 2 weeks post-treatment, when pyridostigmine injections were completed. PBS alone was injected as a control. Personnel performing the injections and all testing were blinded to the agent injected.

α-bungarotoxin labeling whole diaphragms
----------------------------------------

This was performed as described previously ([@b27-0050852]). Five-week-old mice were euthanized and diaphragms were isolated by dissection. They were then fixed briefly in 2% paraformaldehyde and incubated overnight with α-bungarotoxin conjugated to Alexa Fluor 594 (Invitrogen) diluted 1:1000. Samples were mounted with ProLong gold (Invitrogen) and then viewed using an Olympus confocal microscope.

α-bungarotoxin labeling of isolated myofibers
---------------------------------------------

This was performed as described previously ([@b27-0050852]). Mice were euthanized by cervical dislocation and then tibialis anterior muscles were isolated and fixed briefly in 2% paraformaldehyde. Whole muscles were stained with α-bungarotoxin as above, and staining was visualized using a Zeiss LSM 510-Meta confocal microscope.

Electron microscopy
-------------------

Electron microscopy was performed as previously described ([@b9-0050852]).

qRT-PCR
-------

Real time PCR was performed using an ABI Prism 7900 apparatus (Applied Biosystems). Primers are listed below in [Table 1](#t1-0050852){ref-type="table"}.

###### 

Oligonucleotide primer sequences for qRT-PCR

![](DMM009746T1)

###### TRANSLATIONAL IMPACT

**Clinical issue**

Myotubular myopathy (MTM), which is one of several diseases collectively classified as centronuclear myopathies, is a devastating neuromuscular disease of childhood characterized by weakness, severe disability and, in most instances, early lethality. The genetic basis for the disease is known -- mutation of the myotubularin (*MTM1*) gene -- but this knowledge has not translated into the development of viable treatment strategies.

**Results**

In this study, the authors tested the hypothesis that defective transmission at the neuromuscular junction (NMJ) is a pathological and treatable feature of MTM. Their characterization of two existing mouse models of MTM revealed signs consistent with an NMJ disorder, with pathological changes indicating a primary abnormality in the NMJ. Treatment of the mice with pyridostigmine, a known modulator of the NMJ, resulted in significant improvement in motor function.

**Implications and future directions**

These data identify NMJ dysfunction as a previously unrecognized aspect of MTM pathology. No treatments currently exist for MTM, and these findings represent an important step towards translation of the first potential therapy. Pyridostigmine is already approved for other indications, and these preclinical data support initiation of a clinical trial to test the ability of this drug (or other drugs that modulate the NMJ) to improve disease in individuals with MTM. In addition, given the similarities between the pathology of MTM and other centronuclear myopathies, it is likely that NMJ abnormalities are a general and potentially treatable feature in all individuals affected by this group of diseases.

 

Primary myocytes
----------------

Myocytes were derived from extensor digitorum longus muscles from 28-day-old KO animals and WT siblings per an established protocol ([@b34-0050852]). All experiments were performed on myotubes differentiated with 2% horse serum for 10--14 days.

Western blot analysis on skeletal muscle
----------------------------------------

Total protein was extracted from quadriceps or primary myotubes using the T-PER reagent (Pierce). Western blots were performed as detailed previously ([@b14-0050852]). The following antibodies were used: ERK or pERK (1:1000; Cell Signaling), AChR (1:1000; Covance), actin (1:3000; Cell Signaling) and Rab5 (1:500; Abcam). All secondary antibodies were used at 1:2000 (Santa Cruz Biotech).

α-bungarotoxin recycling
------------------------

See Kumari et al. for details ([@b21-0050852]). Myotubes were incubated with Alexa-Fluor-488-conjugated α-bungarotoxin for 45 minutes at room temperature, washed with media, and examined by live imaging 1 hour and 4 hours after α-bungarotoxin exposure using a Leica inverted microscope.

Statistical analyses
--------------------

All statistical analyses were performed using GraphPad Prism. Data was from various studies was entered into the program and then analyzed using a Student's *t*-test.
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